Research programme: antibody therapeutics- Biotheus
Latest Information Update: 11 Apr 2022
At a glance
- Originator Biotheus
- Class Antibodies
- Mechanism of Action Regulatory T-lymphocyte inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Unspecified
Most Recent Events
- 11 Apr 2022 Research programme: Treg depletion - Biotheus is available for licensing as of 11 Apr 2022. https://www.biotheus.com/Business_Partnership.html
- 05 Apr 2022 Early research in Cancer in China (unspecified route)(Biotheus pipeline, April 2022)